# PeptideScanner evidence objects: Efpeglenatide

Every published version of the records placed with Efpeglenatide, one section per evidence object. The section anchor is the object's path id; the JSON twin is https://peptidescanner.com/evidence/v1/peptides/efpeglenatide.json. Selected public evidence only; not medical advice.

- Objects: 7
- Manifest: https://peptidescanner.com/evidence/v1/manifest.json

---

<a id="clinicaltrials-gov-nct01093729-efpeglenatide-v1"></a>

## ClinicalTrials.gov record NCT01093729

> PeptideScanner retained ClinicalTrials.gov record NCT01093729 at 2026-11-16T17:34:46.889Z. Its registry update date was 2014-02-07, and PeptideScanner's reviewed identity mapping was efpeglenatide.

- Evidence object: `story:clinicaltrials-gov-nct01093729-efpeglenatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2014-02-07
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct01093729-efpeglenatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/efpeglenatide.json#clinicaltrials-gov-nct01093729-efpeglenatide-v1
- Content SHA-256: `73f743ab9e559075e47f8b70b86a113b46cf4918ed20fb2738518cfcd59733f9`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT01093729 ([`ctg-observation-nct01093729-2014-02-07-fe19ee5af625`](#source-ctg-observation-nct01093729-2014-02-07-fe19ee5af625))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT01093729 at 2026-11-16T17:34:46.889Z. Its registry update date was 2014-02-07, and PeptideScanner's reviewed identity mapping was efpeglenatide. ([`ctg-observation-nct01093729-2014-02-07-fe19ee5af625`](#source-ctg-observation-nct01093729-2014-02-07-fe19ee5af625))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT01093729 at 2026-11-16T17:34:46.889Z. Its registry update date was 2014-02-07, and PeptideScanner's reviewed identity mapping was efpeglenatide. ([`ctg-observation-nct01093729-2014-02-07-fe19ee5af625`](#source-ctg-observation-nct01093729-2014-02-07-fe19ee5af625))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct01093729-2014-02-07-fe19ee5af625`](#source-ctg-observation-nct01093729-2014-02-07-fe19ee5af625))

### Sources

<a id="source-ctg-observation-nct01093729-2014-02-07-fe19ee5af625"></a>
- **ClinicalTrials.gov record NCT01093729 · retained source version 2014-02-07:fe19ee5af62517592ffc4e10db67e29f5c2ab93c726a6d64bcf346a6963e42ae** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT01093729) (`ctg-observation-nct01093729-2014-02-07-fe19ee5af625`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT01093729." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/efpeglenatide.json#clinicaltrials-gov-nct01093729-efpeglenatide-v1 SHA-256: 73f743ab9e559075e47f8b70b86a113b46cf4918ed20fb2738518cfcd59733f9.

---

<a id="clinicaltrials-gov-nct01452451-efpeglenatide-v1"></a>

## ClinicalTrials.gov record NCT01452451

> PeptideScanner retained ClinicalTrials.gov record NCT01452451 at 2026-11-16T17:34:46.889Z. Its registry update date was 2016-08-09, and PeptideScanner's reviewed identity mapping was efpeglenatide.

- Evidence object: `story:clinicaltrials-gov-nct01452451-efpeglenatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2016-08-09
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct01452451-efpeglenatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/efpeglenatide.json#clinicaltrials-gov-nct01452451-efpeglenatide-v1
- Content SHA-256: `fd70b9c39d72a3d40d4be4e612448092f3049f00377afd24e405c5272bdfefb0`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT01452451 ([`ctg-observation-nct01452451-2016-08-09-27d4cd960e9d`](#source-ctg-observation-nct01452451-2016-08-09-27d4cd960e9d))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT01452451 at 2026-11-16T17:34:46.889Z. Its registry update date was 2016-08-09, and PeptideScanner's reviewed identity mapping was efpeglenatide. ([`ctg-observation-nct01452451-2016-08-09-27d4cd960e9d`](#source-ctg-observation-nct01452451-2016-08-09-27d4cd960e9d))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT01452451 at 2026-11-16T17:34:46.889Z. Its registry update date was 2016-08-09, and PeptideScanner's reviewed identity mapping was efpeglenatide. ([`ctg-observation-nct01452451-2016-08-09-27d4cd960e9d`](#source-ctg-observation-nct01452451-2016-08-09-27d4cd960e9d))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct01452451-2016-08-09-27d4cd960e9d`](#source-ctg-observation-nct01452451-2016-08-09-27d4cd960e9d))

### Sources

<a id="source-ctg-observation-nct01452451-2016-08-09-27d4cd960e9d"></a>
- **ClinicalTrials.gov record NCT01452451 · retained source version 2016-08-09:27d4cd960e9d82e0d07dae7ffc3f257965b0be77f1c16664d4d46d897e3329e2** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT01452451) (`ctg-observation-nct01452451-2016-08-09-27d4cd960e9d`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT01452451." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/efpeglenatide.json#clinicaltrials-gov-nct01452451-efpeglenatide-v1 SHA-256: fd70b9c39d72a3d40d4be4e612448092f3049f00377afd24e405c5272bdfefb0.

---

<a id="clinicaltrials-gov-nct02075281-efpeglenatide-v1"></a>

## ClinicalTrials.gov record NCT02075281

> PeptideScanner retained ClinicalTrials.gov record NCT02075281 at 2026-11-16T17:34:46.889Z. Its registry update date was 2016-08-09, and PeptideScanner's reviewed identity mapping was efpeglenatide.

- Evidence object: `story:clinicaltrials-gov-nct02075281-efpeglenatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2016-08-09
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct02075281-efpeglenatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/efpeglenatide.json#clinicaltrials-gov-nct02075281-efpeglenatide-v1
- Content SHA-256: `d56813e525b1cb415ee4d49265f8ac0d4e115ab963b02098cdf057739338b862`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT02075281 ([`ctg-observation-nct02075281-2016-08-09-2d1d4f05cc5b`](#source-ctg-observation-nct02075281-2016-08-09-2d1d4f05cc5b))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT02075281 at 2026-11-16T17:34:46.889Z. Its registry update date was 2016-08-09, and PeptideScanner's reviewed identity mapping was efpeglenatide. ([`ctg-observation-nct02075281-2016-08-09-2d1d4f05cc5b`](#source-ctg-observation-nct02075281-2016-08-09-2d1d4f05cc5b))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT02075281 at 2026-11-16T17:34:46.889Z. Its registry update date was 2016-08-09, and PeptideScanner's reviewed identity mapping was efpeglenatide. ([`ctg-observation-nct02075281-2016-08-09-2d1d4f05cc5b`](#source-ctg-observation-nct02075281-2016-08-09-2d1d4f05cc5b))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct02075281-2016-08-09-2d1d4f05cc5b`](#source-ctg-observation-nct02075281-2016-08-09-2d1d4f05cc5b))

### Sources

<a id="source-ctg-observation-nct02075281-2016-08-09-2d1d4f05cc5b"></a>
- **ClinicalTrials.gov record NCT02075281 · retained source version 2016-08-09:2d1d4f05cc5b1cbb780abf7442a936265089776d82027d9acc144126a88bfab7** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT02075281) (`ctg-observation-nct02075281-2016-08-09-2d1d4f05cc5b`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT02075281." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/efpeglenatide.json#clinicaltrials-gov-nct02075281-efpeglenatide-v1 SHA-256: d56813e525b1cb415ee4d49265f8ac0d4e115ab963b02098cdf057739338b862.

---

<a id="clinicaltrials-gov-nct02081118-efpeglenatide-v1"></a>

## ClinicalTrials.gov record NCT02081118

> PeptideScanner retained ClinicalTrials.gov record NCT02081118 at 2026-11-16T17:34:46.889Z. Its registry update date was 2016-08-09, and PeptideScanner's reviewed identity mapping was efpeglenatide.

- Evidence object: `story:clinicaltrials-gov-nct02081118-efpeglenatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2016-08-09
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct02081118-efpeglenatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/efpeglenatide.json#clinicaltrials-gov-nct02081118-efpeglenatide-v1
- Content SHA-256: `6dda37ed9a4d5f178790cd759e5fe86f02895d82bb770e926f5f2b0fa80c4ec6`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT02081118 ([`ctg-observation-nct02081118-2016-08-09-718d57902d27`](#source-ctg-observation-nct02081118-2016-08-09-718d57902d27))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT02081118 at 2026-11-16T17:34:46.889Z. Its registry update date was 2016-08-09, and PeptideScanner's reviewed identity mapping was efpeglenatide. ([`ctg-observation-nct02081118-2016-08-09-718d57902d27`](#source-ctg-observation-nct02081118-2016-08-09-718d57902d27))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT02081118 at 2026-11-16T17:34:46.889Z. Its registry update date was 2016-08-09, and PeptideScanner's reviewed identity mapping was efpeglenatide. ([`ctg-observation-nct02081118-2016-08-09-718d57902d27`](#source-ctg-observation-nct02081118-2016-08-09-718d57902d27))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct02081118-2016-08-09-718d57902d27`](#source-ctg-observation-nct02081118-2016-08-09-718d57902d27))

### Sources

<a id="source-ctg-observation-nct02081118-2016-08-09-718d57902d27"></a>
- **ClinicalTrials.gov record NCT02081118 · retained source version 2016-08-09:718d57902d27b464b351854d378d9eecaab37d71adf1441c5e897aef79c4a4f1** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT02081118) (`ctg-observation-nct02081118-2016-08-09-718d57902d27`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT02081118." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/efpeglenatide.json#clinicaltrials-gov-nct02081118-efpeglenatide-v1 SHA-256: 6dda37ed9a4d5f178790cd759e5fe86f02895d82bb770e926f5f2b0fa80c4ec6.

---

<a id="clinicaltrials-gov-nct06174779-efpeglenatide-v1"></a>

## ClinicalTrials.gov record NCT06174779

> PeptideScanner retained ClinicalTrials.gov record NCT06174779 at 2026-11-16T17:34:46.889Z. Its registry update date was 2026-07-07, and PeptideScanner's reviewed identity mapping was efpeglenatide.

- Evidence object: `story:clinicaltrials-gov-nct06174779-efpeglenatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-07-07
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct06174779-efpeglenatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/efpeglenatide.json#clinicaltrials-gov-nct06174779-efpeglenatide-v1
- Content SHA-256: `5fd096f3a250a7377d318387058245ba362f24ba506fa7ec99177838042f550c`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT06174779 ([`ctg-observation-nct06174779-2026-07-07-6ea9ab3dd655`](#source-ctg-observation-nct06174779-2026-07-07-6ea9ab3dd655))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT06174779 at 2026-11-16T17:34:46.889Z. Its registry update date was 2026-07-07, and PeptideScanner's reviewed identity mapping was efpeglenatide. ([`ctg-observation-nct06174779-2026-07-07-6ea9ab3dd655`](#source-ctg-observation-nct06174779-2026-07-07-6ea9ab3dd655))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT06174779 at 2026-11-16T17:34:46.889Z. Its registry update date was 2026-07-07, and PeptideScanner's reviewed identity mapping was efpeglenatide. ([`ctg-observation-nct06174779-2026-07-07-6ea9ab3dd655`](#source-ctg-observation-nct06174779-2026-07-07-6ea9ab3dd655))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct06174779-2026-07-07-6ea9ab3dd655`](#source-ctg-observation-nct06174779-2026-07-07-6ea9ab3dd655))

### Sources

<a id="source-ctg-observation-nct06174779-2026-07-07-6ea9ab3dd655"></a>
- **ClinicalTrials.gov record NCT06174779 · retained source version 2026-07-07:6ea9ab3dd655c26c28cc00c5bf7a9ea59951786aaeeb15a0e24fd391852d6ed9** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT06174779) (`ctg-observation-nct06174779-2026-07-07-6ea9ab3dd655`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT06174779." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/efpeglenatide.json#clinicaltrials-gov-nct06174779-efpeglenatide-v1 SHA-256: 5fd096f3a250a7377d318387058245ba362f24ba506fa7ec99177838042f550c.

---

<a id="clinicaltrials-gov-nct07379333-efpeglenatide-v1"></a>

## ClinicalTrials.gov record NCT07379333

> PeptideScanner retained ClinicalTrials.gov record NCT07379333 at 2026-11-16T17:34:46.889Z. Its registry update date was 2026-05-13, and PeptideScanner's reviewed identity mapping was efpeglenatide.

- Evidence object: `story:clinicaltrials-gov-nct07379333-efpeglenatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-05-13
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct07379333-efpeglenatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/efpeglenatide.json#clinicaltrials-gov-nct07379333-efpeglenatide-v1
- Content SHA-256: `a33c7db44b5beed3ca9e783443d9ab7fa17fd1402af099cdfc39252e52766fe2`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT07379333 ([`ctg-observation-nct07379333-2026-05-13-c599578eaa8d`](#source-ctg-observation-nct07379333-2026-05-13-c599578eaa8d))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT07379333 at 2026-11-16T17:34:46.889Z. Its registry update date was 2026-05-13, and PeptideScanner's reviewed identity mapping was efpeglenatide. ([`ctg-observation-nct07379333-2026-05-13-c599578eaa8d`](#source-ctg-observation-nct07379333-2026-05-13-c599578eaa8d))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT07379333 at 2026-11-16T17:34:46.889Z. Its registry update date was 2026-05-13, and PeptideScanner's reviewed identity mapping was efpeglenatide. ([`ctg-observation-nct07379333-2026-05-13-c599578eaa8d`](#source-ctg-observation-nct07379333-2026-05-13-c599578eaa8d))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct07379333-2026-05-13-c599578eaa8d`](#source-ctg-observation-nct07379333-2026-05-13-c599578eaa8d))

### Sources

<a id="source-ctg-observation-nct07379333-2026-05-13-c599578eaa8d"></a>
- **ClinicalTrials.gov record NCT07379333 · retained source version 2026-05-13:c599578eaa8d429e0152e13caf981fed9266ac8441a80524f20f68e1f1aaac63** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT07379333) (`ctg-observation-nct07379333-2026-05-13-c599578eaa8d`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT07379333." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/efpeglenatide.json#clinicaltrials-gov-nct07379333-efpeglenatide-v1 SHA-256: a33c7db44b5beed3ca9e783443d9ab7fa17fd1402af099cdfc39252e52766fe2.

---

<a id="pubmed-pmid-41403449-efpeglenatide-v1"></a>

## Population pharmacokinetics of efpeglenatide in individuals with obesity and with type 2 diabetes.

> PubMed lists PMID 41403449 in Frontiers in pharmacology as Journal Article, with publication-date metadata of 2025-12-01 (day precision). PeptideScanner associated the retained record with the identity slug efpeglenatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-41403449-efpeglenatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2025-12-19
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-41403449-efpeglenatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/efpeglenatide.json#pubmed-pmid-41403449-efpeglenatide-v1
- Content SHA-256: `4b32c5a177d4feeeba643ed9a4e94edc5ba904c86d141fe718689630dd8919e0`

### Claims and source pins

#### Headline

Population pharmacokinetics of efpeglenatide in individuals with obesity and with type 2 diabetes. ([`pubmed-observation-pmid-41403449-2025-12-19-c4b41020606e`](#source-pubmed-observation-pmid-41403449-2025-12-19-c4b41020606e))

#### Summary

PubMed lists PMID 41403449 in Frontiers in pharmacology as Journal Article, with publication-date metadata of 2025-12-01 (day precision). PeptideScanner associated the retained record with the identity slug efpeglenatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-41403449-2025-12-19-c4b41020606e`](#source-pubmed-observation-pmid-41403449-2025-12-19-c4b41020606e))

#### Paragraph 1

PubMed lists PMID 41403449 in Frontiers in pharmacology as Journal Article, with publication-date metadata of 2025-12-01 (day precision). PeptideScanner associated the retained record with the identity slug efpeglenatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-41403449-2025-12-19-c4b41020606e`](#source-pubmed-observation-pmid-41403449-2025-12-19-c4b41020606e))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-41403449-2025-12-19-c4b41020606e`](#source-pubmed-observation-pmid-41403449-2025-12-19-c4b41020606e))

### Sources

<a id="source-pubmed-observation-pmid-41403449-2025-12-19-c4b41020606e"></a>
- **Population pharmacokinetics of efpeglenatide in individuals with obesity and with type 2 diabetes. · retained source version 1:2025-12-19:current:c4b41020606edfcd3c037cca0eb5c15476eb550109c5e1bd09d0e47050381652** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/41403449/) (`pubmed-observation-pmid-41403449-2025-12-19-c4b41020606e`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Population pharmacokinetics of efpeglenatide in individuals with obesity and with type 2 diabetes." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/efpeglenatide.json#pubmed-pmid-41403449-efpeglenatide-v1 SHA-256: 4b32c5a177d4feeeba643ed9a4e94edc5ba904c86d141fe718689630dd8919e0.

